Urolithin A Missed Its Primary Endpoint in Both Big Trials. The Results It Did Hit Are the Reason People Still Take It.
Urolithin A occupies an unusual position in the longevity supplement market. Most compounds in that market have either enthusiastic marketing built on mouse data, or good human data that nobody has heard of. Urolithin A has two randomized, placebo-controlled human trials published in serious journals, both of which missed their pre-specified primary endpoints, and it is sold heavily anyway. That combination is worth reading carefully rather than treating as either a scandal or a rounding error. The compound itself is not synthetic and not a peptide. It is what certain gut bacteria make out of the ellagitannins in pomegranates, walnuts, strawberries and raspberries, and it is the first well-characterized nutritional compound shown to switch on mitophagy in humans, the process a cell uses to identify and dismantle mitochondria that have stopped working properly. The most consequential single fact about it has nothing to do with any trial result. Only about 40 percent of people carry the bacteria needed to produce urolithin A from food at all, which means the pomegranate advice that circulates alongside it does not apply to most of the people reading it. This article walks through what mitophagy is, what the two large trials measured, why they missed what they missed, what they hit, and where the evidence genuinely stops. It is educational background on published research, not medical advice, a protocol, or a recommendation to take or avoid anything.
Key Takeaways: What the Urolithin A Research Actually Shows
Urolithin A is a metabolite produced by gut bacteria from ellagitannins in pomegranates, walnuts and berries, and it activates mitophagy, the cellular process that removes damaged mitochondria. Roughly 40 percent of people in Western populations carry the gut bacteria that convert dietary ellagitannins into urolithin A, about 10 percent produce related urolithins instead, and about half produce almost none. In the 2022 Cell Reports Medicine trial of 88 sedentary adults aged 40 to 65, the primary endpoint of peak power output was not met, while hamstring peak torque rose about 12 percent on 500 milligrams daily and about 9.8 percent on 1000 milligrams. In the 2022 JAMA Network Open trial of 66 adults aged 65 to 90 taking 1000 milligrams daily, the primary endpoints of six-minute walk distance and muscle ATP production were both missed, while muscle endurance improved significantly at two months, with roughly 95 additional hand-muscle contractions before fatigue against roughly 12 on placebo. Both trials reported reductions in plasma C-reactive protein and in acylcarnitines and ceramides, blood markers associated with mitochondrial workload and inflammation. Urolithin A was safe and well tolerated at 500 and 1000 milligrams daily for four months, and the branded ingredient received FDA Generally Recognized as Safe notification in 2020 and European novel food authorization in 2021. No trial has tested whether urolithin A affects disease risk, disability or lifespan in humans.
What Is Urolithin A and Where Does It Come From?
Urolithin A is not something plants make and not something the human body makes on its own. It is produced by gut bacteria that break down ellagitannins and ellagic acid, compounds found in pomegranates, walnuts, pecans, strawberries and raspberries. When those foods reach the colon, specific bacterial species perform a sequence of chemical steps that strip the parent molecule down to urolithin A, which is then absorbed into the bloodstream. This makes urolithin A a postbiotic rather than a nutrient. The food is the raw material, the bacteria are the factory, and the compound that reaches the tissues is neither of those things. That distinction explains why pomegranate juice and urolithin A supplementation are not interchangeable, and it explains why the research literature moved toward administering the metabolite directly. Direct administration removes the two variables that make the dietary route unreliable, which are whether a person's microbiome can perform the conversion and how much of the parent compound the food actually contained. Urolithin A is a small molecule, not a peptide, and it is taken orally rather than injected.
Most People Cannot Make Urolithin A From Food
Distribution of urolithin metabotypes in Western populations, as characterized by Tomas-Barberan and colleagues. Roughly 40 percent of people carry the gut bacteria that convert dietary ellagitannins into urolithin A. About 10 percent produce urolithin B or isourolithin A instead, and about half produce little or no urolithin at all. This is the single fact that separates eating pomegranates from receiving a measured dose of the metabolite itself.
- Metabotype A (makes urolithin A)
- Metabotype B (makes urolithin B / isourolithin A)
- Metabotype 0 (makes little or no urolithin)
Why Can Most People Not Make Urolithin A From Food?
Most people cannot, and this is the finding that reframes everything else about the compound. Research by Tomas-Barberan and colleagues established that people fall into three urolithin metabotypes based on what their gut bacteria produce from ellagitannins. Roughly 40 percent of a Western population belongs to metabotype A, meaning they produce urolithin A as the main end product. About 10 percent belongs to metabotype B, producing urolithin B or isourolithin A with little or no urolithin A. The remaining half, metabotype 0, produces very little urolithin of any kind. So when an article recommends eating pomegranates for mitochondrial health, that advice is functionally inert for around 60 percent of the people who read it, and there is currently no practical way for an individual to know which group they belong to without specialized metabolite testing. Metabotype also drifts with age and with the state of the microbiome, and it is not a fixed trait a person can rely on. This is the clearest argument for why the trials administered a measured dose of the metabolite rather than asking participants to change their diet, because a dietary intervention would have produced blood levels varying by orders of magnitude between participants.
What Is Mitophagy and Why Does It Decline With Age?
Mitophagy is the cell's process for identifying mitochondria that have stopped working properly, tagging them, and dismantling them so their components can be recycled. Mitochondria generate most of the cell's usable energy, and they degrade over time through oxidative damage to their own membranes and DNA. A damaged mitochondrion is worse than no mitochondrion, because it continues to consume substrate while producing less energy and more reactive byproducts. Healthy cells maintain quality control by continuously culling the failures, and that quality control machinery becomes less efficient with age. The result is a slow accumulation of dysfunctional mitochondria in tissues with high energy demand, particularly skeletal muscle, which is one of the mechanisms proposed to explain age-related loss of muscle endurance and capacity. Mitophagy decline is listed among the recognized hallmarks of aging, which is why a compound that reliably switches the process back on attracted serious research attention. The preclinical case was strong. Work published in Nature Medicine in 2016 by Ryu and colleagues found that urolithin A induced mitophagy in the roundworm C. elegans and extended its lifespan by roughly 45 percent, and that dietary urolithin A improved muscle function in aged mice and running endurance in young ones. Those are animal findings, and the reason the human trials matter is that lifespan results in worms have a poor record of translating.
What Did the First Human Trial of Urolithin A Show?
The first human trial established safety and confirmed that the mechanism operates in people, and it was not designed to show a performance benefit. Andreux and colleagues published it in Nature Metabolism in 2019, running both a single-ascending-dose arm and a four-week repeated-dose arm in healthy sedentary elderly participants. Urolithin A was orally bioavailable, produced no safety signals across the dose range tested, and produced a measurable molecular response in the tissue that mattered. Skeletal muscle biopsies showed shifts in gene expression associated with mitochondrial function, and plasma acylcarnitines fell. Acylcarnitines are the intermediate products of fatty acid transport into mitochondria, and a decline in circulating levels is generally read as mitochondria clearing their substrate more completely rather than leaving partially processed material to spill back into the blood. This was a first-in-human study, so its role in the evidence chain is to license the larger trials rather than to answer whether anyone gets stronger. It did that job. The mechanism that had been demonstrated in worms and mice was shown to engage in human muscle tissue at a dose people could tolerate, which is more than most longevity compounds ever establish.
Did Urolithin A Improve Strength in Middle-Aged Adults?
It improved hamstring strength significantly and failed to improve the outcome the trial was actually built to test. Singh and colleagues published the trial in Cell Reports Medicine in 2022, randomizing 88 sedentary adults aged 40 to 65 to placebo, 500 milligrams of urolithin A daily, or 1000 milligrams daily for four months, with 79 completing. The pre-specified primary endpoint was peak power output during exercise testing, and no significant difference from placebo was observed at either dose. Among the secondary outcomes, average peak torque in the hamstring rose about 12 percent on 500 milligrams with a p-value of 0.027 and about 9.8 percent on 1000 milligrams with a p-value of 0.029, both significant against placebo. Peak oxygen consumption rose roughly 10 percent within the 1000 milligram group, and the same group walked about 33 metres further in the six-minute walk test than at their own baseline, a within-group improvement rather than a difference from placebo. Plasma C-reactive protein fell at both doses and reached significance at 1000 milligrams. One detail deserves emphasis because it cuts against the intuitive reading. The lower dose performed at least as well as the higher one on the strength measure, so the assumption that more urolithin A produces more effect is not supported by this trial.
Hamstring Strength Moved at Both Doses
Change in average peak torque in the hamstring after four months, from the randomized trial of 88 sedentary adults aged 40 to 65 published in Cell Reports Medicine in 2022. Peak torque rose about 12 percent on 500 milligrams daily and about 9.8 percent on 1000 milligrams, both statistically significant against placebo. The lower dose performing at least as well as the higher one is a real feature of the data and argues against the assumption that more urolithin A produces more effect.
What Happened in Adults Aged 65 to 90?
Muscle endurance improved substantially at two months, the improvement had faded into the placebo group by four months, and both primary endpoints were missed. Liu and colleagues published this trial in JAMA Network Open in 2022, randomizing 66 adults with a mean age of 71.7 years to 1000 milligrams of urolithin A daily or placebo for four months. The two primary endpoints were six-minute walk distance and maximal ATP production in hand muscle measured by magnetic resonance spectroscopy. Neither reached significance. Walking distance improved by about 61 metres on urolithin A against about 43 metres on placebo, a difference in the expected direction that the trial was not powered to confirm, and ATP production showed no meaningful group difference in either the hand or the leg. The endurance result was the notable one. At two months, the first dorsal interosseous muscle of the hand managed about 95 additional contractions before fatigue on urolithin A against about 12 on placebo, and the tibialis anterior in the lower leg gained about 41 against about 6. By four months both groups had improved to a similar degree and the difference was no longer significant, which is a genuine limitation and is reported here rather than omitted. Plasma acylcarnitines and C16 and C18 ceramides fell significantly on urolithin A, and C-reactive protein drifted down slightly on the compound while rising on placebo.
The Endurance Result in Adults Aged 65 to 90
Additional muscle contractions before fatigue at two months, from the trial of 66 older adults published in JAMA Network Open in 2022 using 1000 milligrams of urolithin A daily. The first dorsal interosseous muscle of the hand gained about 95 extra contractions on urolithin A against about 12 on placebo, and the tibialis anterior of the lower leg gained about 41 against about 6. By four months the placebo group had caught up and the difference was no longer significant, which is part of why this result is reported here as a two-month finding rather than a four-month one.
- Urolithin A 1000 mg
- Placebo
Why Did Both Trials Miss Their Primary Endpoints?
The primary endpoints were whole-body performance measures, and the compound acts on a cellular process whose effects are slower and more localized than those measures can detect over four months. Peak power output and six-minute walk distance are integrated outcomes that depend on cardiovascular capacity, neuromuscular coordination, motivation and practice effects as much as on mitochondrial quality. Both are also prone to learning effects, where the placebo group improves simply by repeating the test, which is visible in the older-adult trial where placebo walking distance rose by 43 metres on its own. Muscle endurance measured as contractions to fatigue is a narrower measure that isolates the ability of a specific muscle to sustain work, which is closer to what mitophagy would plausibly affect. That is the pattern across both trials: the more specific and mitochondrially proximate the measure, the more likely it moved. This explanation is a reasonable reading of the data and it is not a substitute for a met endpoint. A trial that misses its pre-specified primary endpoint has formally failed to demonstrate its hypothesis, and secondary findings from such a trial are hypothesis-generating rather than confirmatory. Both things are true at once, and any honest account of urolithin A has to hold them together rather than choose the flattering one.
The Pattern: Primaries Missed, Secondaries Hit
Each measured outcome across the two large urolithin A trials, scored by whether it reached statistical significance against placebo. The three grey bars are the pre-specified primary endpoints, and all three were missed. The teal bars are secondary and exploratory outcomes that were met. A trial that misses its primary endpoint has formally failed to prove its hypothesis, no matter how the secondary results read, and that formal failure is the honest headline for urolithin A.
Does Urolithin A Reduce Inflammation and Change Blood Markers?
Three separate human trials reported reductions in circulating markers tied to inflammation and mitochondrial workload, and this is the most reproducible finding in the whole literature. Plasma C-reactive protein fell in both large randomized trials, significantly at the 1000 milligram dose in middle-aged adults and directionally in older adults where it declined slightly on urolithin A while rising in the placebo group. Acylcarnitines fell in the first-in-human study and again in the older-adult trial. Ceramides in the C16 and C18 species fell in the older-adult trial, and elevated ceramides of those chain lengths are associated with insulin resistance and impaired fat oxidation in metabolic research. What this cluster of results supports is that urolithin A changes something measurable about how mitochondria handle fatty acid substrate, and that the change goes in the direction associated with better metabolic health. What it does not establish is that a person feels or lives differently as a result. Biomarkers are proxies, and the history of longevity research is full of compounds that moved a proxy convincingly without moving any outcome that mattered. The biomarker consistency is a reason to keep studying urolithin A, not a reason to treat the question as settled.
What Doses Were Studied and Is Urolithin A Safe?
The trials used 500 and 1000 milligrams daily for four months, and urolithin A was safe and well tolerated at both. The first-in-human study tested single doses up to 2000 milligrams and repeated daily doses up to 1000 milligrams over four weeks without safety signals. The four-month trial in middle-aged adults recorded 102 adverse events across all three arms, most of them mild musculoskeletal complaints attributable to the repeated muscle biopsy procedures the study protocol required rather than to the compound. The older-adult trial reported the same conclusion of safety and tolerability at 1000 milligrams. On the regulatory side, the branded synthetic form received a favourable FDA response to its Generally Recognized as Safe notification in 2020 and was authorized as a novel food in Europe in 2021. That status means the ingredient is accepted as safe for use in food at specified levels. It is not a drug approval and it is not a finding of efficacy, and confusing the two is a common error in supplement marketing. Two limitations bound all of this. The longest controlled human exposure is four months, so nothing is known about taking urolithin A for years. And the safety data belongs to characterized pharmaceutical-grade material, not to arbitrary products whose actual urolithin A content has not been verified.
How Should the Whole Body of Evidence Be Read?
Urolithin A has a stronger human evidence base than almost anything else sold for mitochondrial health, and that evidence base still falls short of demonstrating a benefit anyone would notice. The mechanism is real and confirmed in human muscle tissue, which is a bar most longevity compounds never clear. Safety across three trials at doses up to 1000 milligrams daily for four months is documented. Blood markers of inflammation and mitochondrial substrate handling moved consistently in the favourable direction across independent studies. Muscle strength improved significantly in middle-aged adults and muscle endurance improved significantly at two months in older adults. Set against that, both large trials formally failed by missing their pre-specified primary endpoints, the endurance advantage in older adults did not persist to the four-month timepoint, ATP production did not improve despite being the most direct measure of mitochondrial output, no dose-response relationship appeared, and no trial has tested whether any of this affects disease, disability or lifespan. Around 60 percent of people cannot generate the compound from food, which is the practical fact most dietary advice about pomegranates ignores. The reasonable reading is that urolithin A is an unusually well-evidenced open question rather than a proven intervention, that its effect sizes where they exist are modest and localized to muscle-specific measures, and that anyone weighing it should treat the missed primary endpoints as the headline rather than the footnote. Questions about individual use, and about any interaction with medication or existing conditions, belong with a clinician who can see the full picture. This article is educational and describes published trial data. It is not a protocol and not a recommendation to start or stop anything.
The Whole Body of Evidence on One Axis
Every strand of the urolithin A record arranged as a single schematic map. Teal marks what the human trials established, amber marks the practical caveat that the effect depends on a supplied dose rather than on eating fruit, and grey marks what remains unproven. Bar length is a rough visual weight rather than a shared unit, so read this as a guide to where the evidence is thick and where it thins out. Safety and mechanism sit at the strong end, functional performance sits in the middle, and long-term health outcomes have not been tested at all.
Frequently Asked Questions
Have more questions? Contact us or explore our full peptide intelligence platform.
Related Articles
Does Telomere Length Determine Lifespan? Short Telomeres Track With Earlier Death. The Genetics Say Longer Ones Raise Cancer Risk.
Does telomere length determine lifespan? Short telomeres track with earlier death, yet genetic studies show longer ones raise the risk of several cancers.
Low-Dose Aspirin Added 8 Percent to Male Mouse Lifespan. In 19,114 Healthy Older Adults, It Added No Healthy Years and Deaths Ran Higher.
Does low-dose aspirin help longevity? It extended male mouse lifespan 8%, but the ASPREE trial in 19,114 healthy older adults found no gain and more bleeding.
Is NAD+ a Peptide? No. It Is a Coenzyme Built From Two Nucleotides, and the Peptide Label Comes From the Clinic, Not the Chemistry
Is NAD+ a peptide? No. NAD+ is a coenzyme built from two nucleotides. What NAD+ is used for, what IV NAD+ studies found, and how it differs from SS-31.